Finoriq research workspace
Kiniksa Pharmaceuticals International, plc (KNSA) SEC Filings & Filing Highlights
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops. Review KNSA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Company
- Kiniksa Pharmaceuticals International, plc (KNSA)
- Ticker
- KNSA
- Market Cap
- $4.8B
- Latest Price
- $62.69
- Industry
- Biotech & Pharma
Kiniksa Pharmaceuticals International, plc (KNSA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Kiniksa Pharmaceuticals International, plc (KNSA).
| Event | Form | Date |
|---|---|---|
| Kiniksa Pharmaceuticals International, plc: Shareholder voteOn May 29, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) held its Annual Meeting of Shareholders (the “Annual Meeting”)... | 8-K5.07 | 2026-05-29 |
| The foregoing description of the Deed is qualified in its entirety by reference to the Deed, a...On May 21, 2026, Kiniksa Pharmaceuticals International, plc (the “Company”) entered into a deed of waiver (the “Deed”) with Baker Bros. Adv... | 8-K1.01 | 2026-05-26 |
| On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the “Compa...On April 30, 2026, Eben Tessari informed Kiniksa Pharmaceuticals International, plc (the “Company”) of his decision to resign as Chief Stra... | 8-K5.02 | 2026-05-01 |
| Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execu...Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | 8-K2.02 | 2026-04-28 |
| Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent...Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | 8-K2.02 | 2026-02-24 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.